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Abstract
Purpose: Platelet-rich plasma (PRP) is an autologous substance with adhesive properties. We
aimed at developing and testing the efficacy of a method for PRP preparation in rabbits.
Materials and methods: An in vitro study was carried out to obtain PRP from forty rabbits and
to analyze the number of platelets and type of substance needed to trigger platelet activation. To
induce platelet activation, 5%, 10%, 25% and 50% CaCl solutions were used. Then, an in vivo study
was performed in twelve rabbits to test PRP adhesiveness in lamellar corneal graft. A control group
made up of six rabbits underwent corneal transplantation without using PRP.
Results: 5% CaCl was the most effective concentration in activating PRP, with a mean time of 19
minutes. An attached corneal flap was seen 3 months after surgery. A detached corneal button was
seen in all controls.
Conclusion: Our method was able to produce rabbit-derived PRP with suitable properties for soft
tissue adhesion. These results could be useful for researchers of the growing fields of tissue repair
and experimental transplantation.
Background
The platelet-rich plasma (PRP) is an autologous product
that concentrates a high number of platelets in a small
volume of plasma [1]. This product mimics the last step of
the coagulation cascade, leading to the formation of a
fibrin clot, which consolidates and adheres to the applica-
tion site in a short period of time. Evidencing hemostatic
and healing properties, PRP is able to hold tissues or
materials in a required configuration [2]. Its biocompati-
ble and biodegradable properties prevent the PRP from
inducing foreign body reactions, tissue necrosis, or exten-
sive fibrosis [3]. Absorption of the fibrin clot is achieved
during wound healing within weeks following applica-
tion [4-6]. PRP has been used in humans in different
kinds of transplant procedures such as dentistry [7-9],
orthopedics [10], maxillofacial surgery [11], plastic sur-
gery [12,13] and ophthalmology [14]. In addition, PRP
may be considered a carrier for biological active agents
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[15,16] and a healing substance causing less post-surgical
pain [17,18].
Although the preparation of PRP in humans is well
known [19], its preparation in rabbits is more difficult due
to the reduced volume of blood and the smaller size of
this animal. A blood sample, large enough to prepare PRP
but without being lethal to the animal, should be col-
lected. Reports in the literature differ about the intensity
and duration of blood centrifugation, the number of
platelets present in the PRP, and the use of thrombin or
other factors to activate PRP [1,3,20]. Investigations also
disagree on the puncture site and the quantity of blood
that should be drawn from rabbits [20-22]. Furthermore,
published studies lack an in vivo test of PRP adhesiveness
in rabbits, animal frequently used in experimental trans-
plantation.
The aim of our study was to obtain an ideal PRP solution
for tissue adhesiveness and to test the effectiveness of the
compound on lamellar corneal grafts using an in-vivo rab-
bit eye model.
Materials and methods
The investigation was conducted in two steps. First, an in
vitro study was performed to determine the best method
for obtaining PRP from rabbits. An in vivo study was car-
ried out then to evaluate the adhesiveness of the obtained
PRP to soft tissue.
Forty adult New Zealand white rabbits weighing 3,000
grams each were used. Eighteen were female and twenty-
two were male. The rabbits were treated in accordance
with the guidelines of the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research [23].
In vitro study
Seventy-three blood samples from twenty-eight rabbits
were collected. An 8.7 ml intracardiac blood sample was
drawn under strict aseptic conditions. All animals received
general anesthesia using a combination of midazolam 1
mg/kg intramuscular (Roche, Basel, Switzerland) and ket-
amine 70 mg/kg intramuscular (Fada, Buenos Aires,
Argentina). The blood was aspirated with a 21 G needle.
A 10 ml syringe preloaded with 1.3 ml of Anticoagulant
Citrate Dextrose (ACD) solution was used to avoid coag-
ulation. One millimeter was set apart for cell counting.
The procedure was performed by two investigators (JF and
SG).
Each blood sample was centrifuged for 15 minutes at 72 g
at 4°C resulting in the three following layers: the inferior
layer composed of red cells, the intermediate layer com-
posed of white cells and the superior layer made up of
plasma. The 6 ml plasma layer was centrifuged for another
5 minutes at 1006 g in order to obtain a two-part plasma:
the upper part consisting of 5.5 ml of poor-platelet
plasma (PPP) and the lower part consisting of 0.5 ml of
platelet-rich plasma (PRP). The PPP was first aspirated to
avoid its mixing up with the PRP. The PRP was then gently
aspirated with another pipette and placed in a sterile tube.
The PRP was thus prepared for activation by calcium chlo-
ride (CaCl), which inhibits the blood-thinning effect of
ACD. After activation, PRP turned into a gel-like solution
with adhesive properties and ready for use.
The coagulation time of PRP after CaCl instillation was
evaluated in 250 μl samples placed in Eppendorf tubes
with different CaCl concentrations. Coagulation was
determined by the visualization of the clot at 20°C and
carried out always by the same person (SG). The first anal-
ysis was performed using 5%, 10%, 25% and 50% CaCl
concentrations, which were instilled into two PRP sam-
ples each from two different animals. A comparison was
then made between 5% and 10% CaCl solutions in nine
PRP samples, each obtained from five animals. Finally, a
test was performed using 5% CaCl solution in 47 PRP
samples from twenty one animals (table 1). The samples
were observed for two hours and classified as non-coagu-
lated if coagulation had not occurred during this time.
The platelet count was carried out in the blood drawn and
in the PRP sample with a Neubauer camera using the Bre-
cher and Cronkite direct manual method [24,25].
Table 1: The making process of platelet-rich-plasma in rabbits in vitro
1st step 2nd step 3rd step
CaCl concentration 5% 10% 25% 50% 5% 10% 5%
Number of animals 25 2 1
Number of PRP samples 22 2 2 99 4 7
PRP coagulation yes yes no no yes yes yes
Coagulation time (minutes)
- mean 23 27 no no 17 26 19
- range 18–25 25–31 - - 10–20 20–50 7–39
- st. Deviation - - - - 3.9 10.2 7.4Thrombosis Journal 2006, 4:18 http://www.thrombosisjournal.com/content/4/1/18
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In vivo study
PRP preparation was performed in twelve rabbits using
the same technique as in the in vitro study, and was acti-
vated by 5% CaCl to attach the corneal button as part of
the autologous non-perforating corneal transplantation.
Topical 5% iodopovidone was preoperatively instilled
into the eye and over the eyelids, followed by topical 0.3%
ciprofloxacin (Alcon, Sao Pablo, Brazil). Deep anterior
keratectomy (one third of the stroma), using a 6-mm-
diameter trephine, was done on right eyes under a ZEISS
S5-Pro operating microscope (Zeiss C, Overckochen, Ger-
many). The corneal button was excised according to Mal-
bran's peeling off technique [26]. The flap was then
soaked in autologous PPP and kept at 4°C for about 3
minutes. In the meantime, PRP was activated, trans-
formed into a gel and placed over the stromal surface. The
corneal flap was finally replaced on the stroma. Corneal
graft adherence was manually verified at the end of the
procedure and 30 minutes later using a delicate forceps. A
partial tarsorraphy using three 5-0 silk sutures was carried
out closing two thirds of the palpebral fissure. Twenty-one
percent oxygen was administered to all animals for an
hour after awakening. Topical 0.3% ciprofloxacin (Alcon,
San Pablo, Brazil) and 0.1% dexamethasone (Poen, Bue-
nos Aires, Argentina) were applied 4 times daily up to 14
and 21 days, respectively. The sutures of the partial tarsor-
raphy were removed on day 2.
A control group made up of six rabbits underwent lamel-
lar corneal graft. In this group, the corneal button was
gently placed on the stroma without using PRP. A tarsor-
raphy was also performed and removed on day 2.
Follow-up examinations were daily performed during the
first week and weekly thereafter, using an operating
microscope, a slit-lamp and surgical loupes. Examinations
were carried out with special attention to corneal adhe-
siveness and inflammatory reaction. These features were
photographically documented using a Nikon Coolpix
5700 Digital Camera (Nikon, Tokyo, Japan) on day 2, 7,
30 and 90. Histopathological analyses of the specimens
were done 2, 7, 30 and 90 days after surgery. Histological
specimens were stained with hematoxylin and eosin, peri-
odic acid-Shiff (PAS) and Masson trichrome, and exam-
ined with a Nikon Eclipse E800 microscope (Nikon,
Tokyo, Japan).
Results
In vitro study
All animals survived the blood extraction. Blood samples
were free of clot. PRP was prepared in approximately 40
minutes. The number of platelets in PRP increased with
respect to the number of platelets in the blood sample. In
the PRP, the mean platelet concentration was 807.564
platelets/mm3 (range 622,000 – 1,350,000, SD 211,490)
from an original vein concentration of 320,133 platelets/
mm3 (range 280,000 – 408,000, SD 42,323). The result-
ing Platelet Enrichment Factor [20] was 152%. PRP
treated with 25 % and 50% CaCl concentrations never
coagulated whereas PRP treated with the 10 % CaCl con-
centration coagulated at 26 minutes. The mean coagula-
tion time for 47 samples treated with the 5% CaCl
concentration was 19 minutes (range 7 – 39, SD 7.4)
(table 1).
In vivo study
Animals with PRP showed corneal flap adherence within
20 minutes. An attached graft was seen in all rabbits and
corneal clarity was observed from day 30 onwards (Figure
1). Clinical and histopathological examination of the eyes
revealed no signs of inflammation. A normal interface
between the graft and the host was found at 90 days post-
operatively, as well as an intact epithelium (Figure 2). No
flap complications such as diffuse lamellar keratitis, wrin-
kles, displacements or rotation of the flap were observed.
A detached corneal flap was seen in all control animals
after removing the tarsorraphy.
Discussion
We developed a method for making PRP in rabbits, suc-
cessfully used in non-perforating corneal transplantation.
A comparison of methods used for preparing PRP is
shown in Table 2. Blood coagulation problems are more
frequently seen in female than in male rabbits [20]. This
observation could influence rabbit PRP production. Any-
how, these differences do not seem to be relevant in
humans [27]. It should be noted that the blood sample in
our investigation had to be collected intracardiacally
because we were not able to avoid blood coagulation by
using different puncture sites, such as the ear or femoral
vein. There is a wide range of variation in the intensity and
duration of centrifugation among research studies. Ideal
platelet counts differ among researchers. The machine and
software used seem to play a role since rabbit derived
platelets are smaller than those of humans [8]. Rabbits
require specific software. That is why we carried out the
platelet counts by direct observation. We thought that, by
doing so, we would be able to get a more accurate count.
Although some researchers have claimed that the best
platelet concentration for producing PRP is 1 million/dl,
this remains unclear. We tested the adhesiveness of PRP
and can conclude that a Platelet Enrichment Factor of
152% seems to be useful at least for soft tissue adhesion.
Other tissue adhesives have also been used in lamellar
keratoplasty in rabbits and humans [28,29] and new syn-
thetic glues like biodendrimer [30] and light-activated
[31] adhesives are being tested in ophthalmology. Most of
them have functional similarities but differ in origin andThrombosis Journal 2006, 4:18 http://www.thrombosisjournal.com/content/4/1/18
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compounds. The major difference with PRP is that these
commercial products are not autologous [1].
PRP is always autologous. Nevertheless, bovine thrombin
has been used to activate PRP in previous studies without
Clinical and histopathological results 90 days after lamellar corneal transplantation Figure 2
Clinical and histopathological results 90 days after lamellar corneal transplantation. Clear cornea (A) and attached 
lamellar flap with a normal appearence (B) (H&E stain, 60×) is seen at 90 days postoperative.
Clinical and histopathological results 30 days after lamellar corneal transplantation Figure 1
Clinical and histopathological results 30 days after lamellar corneal transplantation. An attached lamellar flap is 
seen with a suitable transparency at 30 days postoperative (A). This flap without epithelial defects is seen under Masson tech-
nique occupying the superficial third of the cornea.T
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Table 2: The comparison of methods used for PRP preparation in rabbits
Study Rabbit Blood Samples AC Centrifugation Hct PRP Platelets cells Count EF Activation type Adhesive Test
T F M S ml Type 1st 2nd % ml Vein PRP %
Efeoglu et al [20] 23 13 10 Vein 11 EDTA 300 g/10' 5000 g/5' NS NS 555.000 3.134.500 465 not done not done
Butterfield et al [22] 12 0 12 Ear artery 21 citrate 150 g/20' 400 g/10' NS 1 468.000 2.061.000 340 CaCl + BT not done
Hokugo et al [28] 15 NS NS NS 10 citrate 2400 rpm/10' 3600 rpm/10' NS 0,8 200.000 1.200.000 500 Fib + BT not done
Ohya et al [29] 18 18 0 NS 30 NS 203 g/5' 1050 g/5' NS 3 227.000 864.000 281 CaCl + BT not done
Jung et al [30] 16 NS NS NS 9 citrate 150 g/20' 500 g/20' NS 0,5 NS NS NS CaCl + BT not done
Present study 40 18 22 Heart 10 citrate 72 g/15' 1006 g/5' 41 1 320.133 807.564 152 CaCl done
T: Total; F: Female; M: Male; Hct: Hematocrit; S: Source; AC: Anticoagulation; EDTA: Ethylenediaminetetraacetic acid; NS: Not Specified; CaCl: calcium chloride; Fib: Fibrinogen; BT: Bovine Thrombin; EF: 
Enrichment Factor
Observation: centrifugation values by Hokugo et al were reported in centrifuge rotor speed (rpm). Not enough data was available to make the conversion to times gravidity (g).Thrombosis Journal 2006, 4:18 http://www.thrombosisjournal.com/content/4/1/18
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respecting the autologous aspect [22,32-34]. In our inves-
tigation, a chemical substance (5% CaCl concentration),
was found suitable for triggering PRP activation. This
could avoid the use of heterologous blood components
which can cause immune reactions, and in turn, lead to
negative results that could be falsely ascribed to PRP.
Several variables should be carefully monitored during
PRP preparation. Special care must be placed on blood
extraction tools, machines for blood centrifugation and
CaCl solutions to prevent contamination of the com-
pound. The process must be kept sterile and precisely
suited to separate platelets from red blood cells. Unless
platelet sequestration is done carefully and without caus-
ing any damage, platelets will no longer be able to secrete
growth factors actively. PRP failure in previous studies
may have resulted from non-adherence to these recom-
mendations [21].
PRP, as tissue adhesive, has different applications in med-
icine [7]. It has also been used as carrier for pharmaceuti-
cal molecules, as antiangiogenic agents, and growth
factors [32,35,36]. Gene therapy may benefit from PRP in
future investigations since the presence of an adenoviral
vector in the gel did not affect its properties [37]. It is also
worth mentioning the recent use of PRP as cell supporter
in corneal limbal epithelial cell transplantation [38].
In this experimental study in rabbits, PRP as an adhesive
was able to attach the corneal button in the setting of non-
perforating corneal transplantation. The corneal flap,
about one third of the corneal thickness, remained
attached up to three months post-operatively. Our survey
on PRP preparation disclosed several difficulties that are
yet to be overcome. This study could be taken as a guide-
line for rabbit-derived PRP preparation. We hope that the
comments and data herein prove useful to researchers of
the growing fields of platelet cell and experimental trans-
plantation. Further studies are currently underway to eval-
uate the corneal wound healing response in the presence
of PRP adhesive.
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